Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about the convenience and safety of subcutaneous delivery of daratumumab in multiple myeloma patients.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about very impressive data showing the efficacy of daratumumab, lenalidomide, and dexamethasone to treat relapsed or refractory multiple myeloma patients.
The FDA issued a warning for cancer patients to not use of the drug PNC-27 which is a non-approved cancer treatment sold online, mostly in other countries.
Pushkal Garg, MD, of Alnylam Pharmaceuticals discusses the recent data on the efficacy and safety of givosiran to treat hepatic porphyrias.
David Kuter, MD of Massachusetts General Hospital talks about the global Gaucher earlier diagnosis consensus (GED-C) initiative that is being developed to help clinicians diagnose many of the Gaucher disease patients that may not be getting properly diagnosed because their symptoms are not as severe.
David Kuter, MD, of Massachusetts General Hospital provides an overview of Gaucher disease and how it is currently managed.
Pushkal Garg, MD, of Alnylam Pharmaceuticals discusses the recent data on the efficacy and safety of fitusiran to treat patients with hemophilia.
Jeffrey Jones, MD, MPH talks about a recent phase 1b study involving the use of obinutuzmab, ibritinib, and venetoclax to treat relapsed/refractory chronic lymphocytic leukemia (CLL).
The developer of the drug—Seattle Genetics—stated that 6 patients have been identified with hepatotoxicity and 4 of them have died.
The FDA approved Shire’s Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for children under 12 with hemophilia A and for use in surgical settings for adult and pediatric patients.